Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ustekinumab induction and maintenance study in moderately to severely active Crohn's disease
jRCT2031200345Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at induction Week 8, Adverse events up to Week 74 and 8 more. Started Aug 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031200345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200345.